Keytruda (pembrolizumab)

pCPA File Number: 21386
Negotiation Status:
Concluded with an LOI
Indication(s):
Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor/Manufacturer:
Merck Canada Inc.
CDA-AMC Project Number:
PC0216-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: